NASDAQ:FREQ Frequency Therapeutics (FREQ) Stock Price, News & Analysis → Was the Great Financial Crisis fun? (From Brooks Enterprises) (Ad) Free FREQ Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.28▼$0.3250-Day Range$0.22▼$14.9852-Week Range$0.18▼$16.00Volume309,164 shsAverage Volume822,537 shsMarket Capitalization$10.94 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Frequency Therapeutics alerts: Email Address Ad The Oxford ClubAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time to watch it.Watch Alex's "Next Magnificent Seven" presentation now. About Frequency Therapeutics Stock (NASDAQ:FREQ)Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.Read More Ad The Oxford ClubAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time to watch it.Watch Alex's "Next Magnificent Seven" presentation now. FREQ Stock News HeadlinesMay 29, 2024 | msn.comHow to know when it's time to quit therapyMay 29, 2024 | msn.comReducing cancer treatment frequency could cut greenhouse gas emissionsMay 29, 2024 | msn.comNeed some rejuvenation? Hard to beat Wind Therapy on a Barnegat Bay sailboatMay 28, 2024 | finanznachrichten.deIRLAB Therapeutics: IRLAB Presents at Redeye Growth Day 30 MayMay 27, 2024 | finanznachrichten.deIRLAB Therapeutics: IRLAB Appoints Kristina Torfgård as New CEOMay 24, 2024 | msn.comEverything You've Ever Wanted to Know (But Were Scared to Ask) About Menopausal Hormone TherapyMay 23, 2024 | finanznachrichten.deIRLAB Therapeutics: IRLAB Strengthens its Liquidity by Drawing SEK 25 million on a Previously Secured Loan FacilityMay 23, 2024 | msn.comLemon verbena extract boosts sleep qualityMay 21, 2024 | msn.comUnlocking the Potential: Exploring Exosomes and Stem Cell Therapy for Home UseMay 20, 2024 | finance.yahoo.comNature Medicine Highlights Significant Improvement in Hand and Arm Function After Spinal Cord Injury with Use of ONWARD® ARC-EX® TherapyMay 17, 2024 | msn.comThe Best Red Light Therapy Devices for Wrinkles, Acne, and Fine LinesMay 17, 2024 | msn.comDoes Red Light Therapy Stimulate Collagen?May 17, 2024 | finance.yahoo.comBayer’s non-hormonal therapy reduces hot flashes in Phase III trialsMay 16, 2024 | msn.comCognitive behavioral therapy might improve sleep quality in teens suffering from anxietyMay 16, 2024 | markets.businessinsider.comBuy Rating for Ovid Therapeutics Based on Promising Drug Trials and Strategic PartnershipsMay 11, 2024 | msn.comWhat is Vitamin IV therapy and how does it work?May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Trevi Therapeutics Amid Promising Clinical Advances and Solid Financial PositionMay 9, 2024 | finanznachrichten.deAkebia Therapeutics, Inc.: Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 8, 2024 | uk.finance.yahoo.comQ1 2024 Viridian Therapeutics Inc Earnings CallMay 8, 2024 | msn.comXyloCor Therapeutics Announces Promising Results for Gene Therapy in Treating Refractory AnginaMay 8, 2024 | finance.yahoo.comResearchers hit ‘milestone’ in light therapy for spinal cord injury studyMay 7, 2024 | finance.yahoo.comKromaTiD Expands Their Gene Therapy Analytic Assay Suite with the Addition of GLP Genomic Integrity Karyotyping ServicesMay 6, 2024 | finanznachrichten.deIRLAB Therapeutics: IRLAB: Invitation to the Interim Report for Q1 2024 Presentation and WebcastMay 6, 2024 | finanznachrichten.deIRLAB Therapeutics: IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757May 4, 2024 | msn.comGene Therapy Allowing Heart to Grow New Blood Vessels Supported by Early DataSee More Headlines Receive FREQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Frequency Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today6/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:FREQ CUSIPN/A CIK1703647 Webwww.frequencytx.com Phone781-315-4600FaxN/AEmployees46Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-81,580,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-107.67% Return on Assets-61.40% Debt Debt-to-Equity RatioN/A Current Ratio5.81 Quick Ratio5.81 Sales & Book Value Annual Sales$14.07 million Price / Sales0.78 Cash FlowN/A Price / Cash FlowN/A Book Value$1.96 per share Price / Book0.15Miscellaneous Outstanding Shares36,520,000Free Float30,385,000Market Cap$10.94 million OptionableNot Optionable Beta0.84 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. David L. Lucchino (Age 53)Co-Founder, President, CEO & Director Comp: $1.02MMr. Richard J. Mitrano (Age 52)Vice President of Finance & Operations Mr. James P. AbelyAssociate General Counsel & SecretaryDr. John L. LaMattina Ph.D. (Age 73)Senior Advisor & Member of PCA Regenerative Medicine Advisory Board Key CompetitorsLexaria BioscienceNASDAQ:LEXXCleneNASDAQ:CLNNGain TherapeuticsNASDAQ:GANXOcuphire PharmaNASDAQ:OCUPImmuneeringNASDAQ:IMRXView All CompetitorsInsidersDavid L LucchinoSold 2,865 sharesTotal: $1,719.00 ($0.60/share)Richard J MitranoSold 227 sharesTotal: $143.01 ($0.63/share)David L LucchinoSold 2,895 sharesTotal: $1,881.75 ($0.65/share)Richard J MitranoSold 234 sharesTotal: $156.78 ($0.67/share)David L LucchinoSold 2,881 sharesTotal: $1,815.03 ($0.63/share) FREQ Stock Analysis - Frequently Asked Questions Should I buy or sell Frequency Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Frequency Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" FREQ shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FREQ, but not buy additional shares or sell existing shares. View FREQ analyst ratings or view top-rated stocks. How were Frequency Therapeutics' earnings last quarter? Frequency Therapeutics, Inc. (NASDAQ:FREQ) issued its quarterly earnings results on Monday, November, 15th. The company reported ($0.73) earnings per share for the quarter, missing analysts' consensus estimates of ($0.57) by $0.16. What other stocks do shareholders of Frequency Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Frequency Therapeutics investors own include AbbVie (ABBV), Fulcrum Therapeutics (FULC), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Pfizer (PFE), Taiwan Semiconductor Manufacturing (TSM), Atreca (BCEL), Cidara Therapeutics (CDTX), Clovis Oncology (CLVS) and Chimerix (CMRX). When did Frequency Therapeutics IPO? Frequency Therapeutics (FREQ) raised $102 million in an IPO on Thursday, October 3rd 2019. The company issued 6,700,000 shares at a price of $14.50-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Mizuho Securities was co-manager. This page (NASDAQ:FREQ) was last updated on 6/4/2024 by MarketBeat.com Staff From Our PartnersWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises| SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club| Sponsored[Webinar] Understanding Covered CallsDiscover the details of this option-selling strategy.OIC| SponsoredWhat’s Pelosi Buying Now?They Make the Top Investors Look Like Amateurs They beat the market for three years straight… avoided some ...Altimetry| Sponsored[Urgent!] Generational Wealth GameplanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan ...Crypto 101 Media| SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings| SponsoredAre You Positioned For The New Energy Goldrush?Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro| SponsoredClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an eff...Crypto Swap Profits| Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Frequency Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Frequency Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.